drugset / Trial / NCT02251873

Evaluation of the Pharmacokinetic Interaction of Steady State Tipranavir and Ritonavir or Tipranavir and Ritonavir With Single Dose Didanosine in Healthy Volunteers

NCT02251873

Phase 1 Completed 50 enrolled Boehringer Ingelheim
RandomizedParallel-groupOpen-labelTreatment

Summary

Study to characterise the effects of concurrent tipranavir (TPV) and ritonavir (RTV) administration on the single dose pharmacokinetics of didanosine (ddI), to characterise the effects of single-dose ddI on the pharmacokinetics of TPV and RTV and to assess the short-term safety of this combination

Timeline

Start
2001-09
Primary completion
2002-03
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Didanosine Small molecule 400 mg
Subject Ritonavir Other / unclassified 100 mg
Subject Ritonavir Other / unclassified 200 mg
Subject Tipranavir Small molecule 500 mg
Subject Tipranavir Small molecule 750 mg

Indications

No indication recorded.